PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Sanchez-Garrido, M.A.* ; Serrano-López, V.* ; Ruiz-Pino, F.* ; Vázquez, M.J.* ; Rodríguez-Martín, A.* ; Torres, E.* ; Velasco, I.* ; Rodríguez, A.B.* ; Chicano-Gálvez, E.* ; Mora-Ortiz, M.* ; Ohlsson, C.* ; Poutanen, M.* ; Pinilla, L.* ; Gaytán, F.* ; Douros, J.D.* ; Yang, B.* ; Müller, T.D. ; DiMarchi, R.D.* ; Tschöp, M.H. ; Finan, B.* ; Tena-Sempere, M.*

Superior metabolic improvement of polycystic ovary syndrome traits after GLP1-based multi-agonist therapy.

Nat. Commun. 15:8498 (2024)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Polycystic ovary syndrome (PCOS) is a heterogeneous condition, defined by oligo-/anovulation, hyper-androgenism and/or polycystic ovaries. Metabolic complications are common in patients suffering PCOS, including obesity, insulin resistance and type-2 diabetes, which severely compromise the clinical course of affected women. Yet, therapeutic options remain mostly symptomatic and of limited efficacy for the metabolic and reproductive alterations of PCOS. We report here the hormonal, metabolic and gonadal responses to the glucagon-like peptide-1 (GLP1)-based multi-agonists, GLP1/Estrogen (GLP1/E), GLP1/gastric inhibitory peptide (GLP1/GIP) and GLP1/GIP/Glucagon, in two mouse PCOS models, with variable penetrance of metabolic and reproductive traits, and their comparison with metformin. Our data illustrate the superior efficacy of GLP1/E vs. other multi-agonists and metformin in the management of metabolic complications of PCOS; GLP1/E ameliorates also ovarian cyclicity in an ovulatory model of PCOS, without direct estrogenic uterotrophic effects. In keeping with GLP1-mediated brain targeting, quantitative proteomics reveals changes in common and distinct hypothalamic pathways in response to GLP1/E between the two PCOS models, as basis for differential efficiency. Altogether, our data set the basis for the use of GLP1-based multi-agonists, and particularly GLP1/E, in the personalized management of PCOS.
Impact Factor
Scopus SNIP
Altmetric
14.700
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Beta-cell Function; Luteinizing-hormone; Ovulation Induction; Insulin-resistance; Corrects Obesity; Metformin; Women; Management; Clomiphene; Glp-1
Sprache englisch
Veröffentlichungsjahr 2024
HGF-Berichtsjahr 2024
ISSN (print) / ISBN 2041-1723
e-ISSN 2041-1723
Zeitschrift Nature Communications
Quellenangaben Band: 15, Heft: 1, Seiten: , Artikelnummer: 8498 Supplement: ,
Verlag Nature Publishing Group
Verlagsort London
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)
POF Topic(s) 90000 - German Center for Diabetes Research
30201 - Metabolic Health
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-501900-221
G-502200-001
Förderungen European Research Council ERC-CoG Trusted
EU funds from FEDER Program
Flexi-Met, Instituto de Salud Carlos III, Ministerio de Sanidad, Spain
Junta de Andalucia, Spain
University of Cordoba-FEDER
EU
Instituto de Salud Carlos III
Ministerio de Sanidad, Spain
German Research Foundation
German Center for Diabetes Research (DZD e.V.)
Agencia Estatal de Investigacion, Spain
DOI 10.1038/s41467-024-52898-y
WOS ID 001326736000023
Scopus ID 85205527171
PubMed ID 39353946
Erfassungsdatum 2024-11-04
[➜Korrektur melden]